Clinical Trial Update: Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients [Phase 1, Phase 2]

View source ↗

Summary

Early-phase safety and tolerability study evaluating a chimeric antigen receptor regulatory T cell (CAR-Treg) therapy in living donor kidney transplant recipien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Transplant Rejection

Drugs mentioned

• CAR-Treg Cell Therapy (Chimeric Antigen Receptor Regulatory T Cell Therapy) (CAR-Treg)

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Kidney Transplant Rejection, End Stage Renal Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING